


Texas Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Texas from January 2017 through December 2017.

Key Texas Findings



Rejection Rate:

30%



Appeals Rate:

27%



Final Rejections:

7,396

Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Federal Employee Benefit Plan **82%**
- Tricare Military Health SVC SYS **44%**
- United Health Group **41%**
- Express Scripts **39%**

The following had **the lowest rates of rejection:**

- Aetna **18%**
- Humana Health Plan **12%**



The following table details claims data for the Texas managed care organizations that received at least 400 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Federal Employee Benefit Plan	82%	450	371
Tricare Military Health SVC SYS	44%	629	275
United Health Group	41%	3,315	1,349
Express Scripts	39%	1,225	477
CVS Health	38%	1,544	581
Health Care Services Corporation HCSC	33%	2,880	940
Teacher Retirement System Of Texas TRS	26%	1,174	302
Employees Retirement System Of Texas ERS	25%	1,128	281
Cigna Healthcare	22%	1,289	284
Aetna	18%	2,937	531
Humana Health Plan	12%	4,157	490

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

